Eli Lilly and (LLY) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $7.48
- Estimate
- $6.35
- Surprise
- +17.9%
- Revenue (period 2026-09-30)
- $24.40B
- Score today
- 6.4/10
Revenue source: xbrl.
How the report landed
Eli Lilly and (LLY) beat the $6.35 estimate with adjusted EPS of $7.48 — a large 17.9% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates LLY Buy (Wait) at 6.4/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +17.9% surprise compares with a +20.0% four-quarter average.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (2.5% away)
- Leverage penalty (D/E 1.6): -1.0
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $1373.70
- Entry target
- $1150.23
- Stop
- $1097.27
The stock trades at 46.1× trailing but 28.3× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 78 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 1.8× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.
LLY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $1224.46B
- P/E (fwd)
- 28.3
- P/E (ttm)
- 46.1
- 52-week range
- $812.25–$1408.38
- Off 52-week high
- 2.5%
- RSI (14)
- 78
- Volume vs avg
- 1.84×
- Score today
- 6.4/10